NETSCOUT Announces Availability of Omnis Cyber Intelligence
2.11.2021 14:55:00 EET | Business Wire | Press release
NETSCOUT SYSTEMS, INC., (NASDAQ: NTCT), a leading provider of cybersecurity, service assurance, and business analytics solutions, today announced the availability of Omnis® Cyber Intelligence (OCI), the industry's fastest and most scalable network security software solution, built on the foundation of the industry's most prominent network monitoring and packet recording and analysis technology. It uniquely detects and investigates suspicious activities in real-time and retrospectively, identifies threats early in the attack life cycle to prevent infections from spreading, stops future attacks, and identifies compromised assets.
With cyberattacks increasing and breaches making front-page news, IT security teams find that their existing tools are no match for this growing threat, and both their expenses and their cyber risk are growing out of control. This the case because the typical data sets feeding these tools are reactive, not granular, and do not extend to the earliest indications of a potential attack.
NETSCOUT's approach to turn the situation around is to leverage its market-leading visibility technology to increase the range and depth of security intelligence and make it accessible to security teams in real-time. The solution consists of an analytics stack and cyber security software sensors called Omnis CyberStreams.
NETSCOUT's Omnis Cyber Intelligence arms security teams with proactive, actionable intelligence helping them to:
- Perform continuous scanning and analysis for reconnaissance to detect attacks earlier, minimizing exposure and, in many cases, thwarting the threat.
- Rapidly access high-resolution historical evidence far back in time to understand how an attack started to prevent similar breaches and stop ongoing malicious activity.
- Monitor exposed attack surfaces within their infrastructure to optimize the effectiveness of the defenses deployed.
- Evaluate the extent of penetration and impacted assets when attacks occur to prevent malware from spreading.
- Deploy on-premises, in virtualized data centers, and the public cloud, supporting an organization's evolving deployment preferences without impacting security governance and workflows.
- Integrate with their security ecosystem through APIs and partnerships with leading vendors such as Splunk, Palo Alto Networks, and AWS.
As a result, the effectiveness of customers' existing security tools and the productivity of analysts improve, and they can get ahead of the vicious cycle of both rising costs and rising cyber risk.
"NETSCOUT's unique ASI technology allows companies to truly unlock the actionable intelligence embedded in network transactions and packets," said Christopher Kissel, research director, security and trust products, IDC. "Where others have failed, NETSCOUT has made the use of packet data fast and affordable with their patented metadata extraction, intelligent reduction, and indexing. Omnis Cyber Intelligence provides security analysts with the information they need to quickly and accurately assess the scope and scale of an incident and reduce the associated risk and negative impact."
"Enterprises have invested heavily in cybersecurity solutions, but they are largely ineffective because they lack the actionable visibility needed to spot attacks before they have broad impact," stated Sanjay Munshi, vice president, product management, NETSCOUT. "As attack surfaces expand, the Omnis Cyber Intelligence solution extends throughout the infrastructure, integrates into existing ecosystems, and becomes part of the growing movement towards XDR, using meaningful metadata, or smart data, and powerful cyber analytics to quickly get to the root cause of the cybersecurity issue and mitigate risk."
For more information about the Omnis Cyber Intelligence solution, please visit https://www.netscout.com/solutions/omnis-security.
About NETSCOUT
NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) helps assure digital business services against security, availability, and performance disruptions. Our market and technology leadership stems from combining our patented smart data technology with smart analytics. We provide real-time, pervasive visibility and insights customers need to accelerate and secure their digital transformation. Omnis® Cyber Intelligence delivers the fastest and most scalable network security solution available on the market. NETSCOUT nGenius® service assurance solutions provide real-time, contextual analysis of service, network, and application performance. And Arbor® Smart DDoS Protection by NETSCOUT products help protect against attacks that threaten availability and advanced threats that infiltrate networks to steal critical business assets. To learn more about improving service, network, and application performance in physical or virtual data centers or in the cloud, and how NETSCOUT's security and performance solutions can help you move forward with confidence, visit www.netscout.com or follow @NETSCOUT on Twitter, Facebook, or LinkedIn.
©2021 NETSCOUT SYSTEMS, INC. All rights reserved. NETSCOUT, the NETSCOUT logo, Guardians of the Connected World, Adaptive Service Intelligence, Arbor, ATLAS, Cyber Threat Horizon, InfiniStream, nGenius, nGeniusONE, and Omnis are registered trademarks or trademarks of NETSCOUT SYSTEMS, INC., and/or its subsidiaries and/or affiliates in the USA and/or other countries. Third-party trademarks mentioned are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211102005446/en/
Contact information
Editorial:
Maribel Lopez
Manager, Marketing & Corporate Communications
+1 781 362 4330
maribel.lopez@netscout.com
Chris Shattuck
Finn Partners for NETSCOUT
+1 404 502 6755
NETSCOUT-US@FinnPartners.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 12:52:00 EEST | Press release
The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 12:00:00 EEST | Press release
The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that elevates high-performance riders and horses to their rightful place on the world stage. Built on merit, integrity, and excellence, the PJL brings together the world’s best athletes to compete for the biggest prize pot in the discipline’s history, helping to create a more resilient, long-term financial model for the sport. Represented by sixteen teams, the PJL will introduce an industry-first rider selection process from a pool of 250 of the world’s leading riders. World-class, immersive events will unfold across fourteen ic
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 12:00:00 EEST | Press release
Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkbj) for the treatment of spastic cerebral palsy (CP). On top of safety and tolerability, the study will evaluate improvements in daily functioning, quality of life, motor abilities, and neurodevelopmental measures of the Cenegermin-bkbj intranasal formulation. CP is the most common motor disability in childhood, caused by injury or changes during early brain development. The most prevalent form, spastic CP, leads to muscle stiffness and difficulty with movement.2 “Cerebral palsy is a devastating disease, and for patients and families there are still no proven treatments beyond supportive care,” said Marcello Allegretti, Chief Scientific Officer at Dompé. “With our emerging intranasal NGF p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
